The Bergen 4-Day Panic Disorder Treatment: A Pilot Study

The Bergen 4-Day Panic Disorder Treatment: A Pilot Study - B4DT-PANIK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038563

Enrollment

Registered

2025-12-02

Start date

2026-01-19

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F41.0

Interventions

Group 1: The B4DT is conducted on four consecutive days in a group of 3 to 4 patients by the same number of therapists. The first day in the group setting is dedicated to manualized psychoeducation a

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Diagnosed with panic disorder (ICD-10: F41.0) 18 to 75 years of age Willingness and consent to participate in the study (informed consent) Stable pharmacological treatment before treatment start

Exclusion criteria

Exclusion criteria: Acute suicidality Psychotic symptoms Substance dependence

Design outcomes

Primary

Measure	Time frame
The primary outcome parameter is the change in panic symptomatology, assessed with the Panic Disorder Severity Scale (PDSS) from t0 to t1 and after the two follow-ups (t2 and t3). Response to treatment (“responders” = 40% reduction in PDSS score) and remission status (PDSS score of = 5 for panic disorder and = 7 for panic disorder with agoraphobia) are also measured using the PDSS.	—

Secondary

Measure	Time frame
Secondary outcome parameters are the change in self-reported panic symptoms PDSS-SR), depression (PHQ-9) as well as self-esteem (RSES) and quality of life (WHOQoL-Bref) and experience avoidance/psychological flexibility (BEAQ) as well as the general level of functioning (GAF). In addition, at baseline (t0), motivation and previous therapy experiences are assessed. At t1 group processes (Group Questionnaire GQ-D) are assessed. From t1 to t3, patient satisfaction (ZUF-8), subjective evaluation of the intervention, and side effects (INEPS) will be measured. Questionnaires on exposures as well as on other therapy measures will be given at t2 and t3. At the four treatment days (at the beginning and end), patients will be asked questions to evaluate the treatment process (e.g., self-efficacy, treatment success, motivation, rating of distress, violation of expectancy).	—

Measure

Time frame

Secondary outcome parameters are the change in self-reported panic symptoms PDSS-SR), depression (PHQ-9) as well as self-esteem (RSES) and quality of life (WHOQoL-Bref) and experience avoidance/psychological flexibility (BEAQ) as well as the general level of functioning (GAF). In addition, at baseline (t0), motivation and previous therapy experiences are assessed. At t1 group processes (Group Questionnaire GQ-D) are assessed. From t1 to t3, patient satisfaction (ZUF-8), subjective evaluation of the intervention, and side effects (INEPS) will be measured. Questionnaires on exposures as well as on other therapy measures will be given at t2 and t3. At the four treatment days (at the beginning and end), patients will be asked questions to evaluate the treatment process (e.g., self-efficacy, treatment success, motivation, rating of distress, violation of expectancy).

—

Countries

Germany

Contacts

Public ContactLena Jelinek

Universitätsklinikum Hamburg-Eppendorf, Zentrum für Psychosoziale Medizin Klinik und Poliklinik für Psychiatrie und Psychotherapie

l.jelinek@uke.de+49 40-7410 55868

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026